Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).

@article{Yamaguchi2015SafetyAE,
  title={Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).},
  author={Osamu Yamaguchi and Hidehiro Kakizaki and Yukio Homma and Yasuhiko Igawa and Masayuki Takeda and Osamu Ishizaki Nishizawa and Momokazu Gotoh and Masaki Yoshida and Osamu Yokoyama and Narihito Seki and Akira Okitsu and Takuya Hamada and Akiko Kobayashi and Kentarou Kuroishi},
  journal={BJU international},
  year={2015},
  volume={116 4},
  pages={612-22}
}
OBJECTIVE To examine the safety and efficacy of mirabegron as 'add-on' therapy to solifenacin in patients with overactive bladder (OAB). PATIENTS AND METHODS This multicentre, open-label, phase IV study enrolled patients aged ≥20 years with OAB, as determined by an OAB symptom score (OABSS) total of ≥3 points and an OABSS Question 3 score of ≥2 points, who were being treated with solifenacin at a stable dose of 2.5 or 5 mg once daily for at least 4 weeks. Study duration was 18 weeks… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…